Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for acute leukemias

P C Caron1, D A Scheinberg

  • 1Clinical Immunology Services, Memorial Sloan-Kettering Cancer Center, New York City, NY 10021.

Current Opinion in Oncology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies.

Leukemia·2017
Same author

CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes.

Leukemia·2017
Same author

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.

Leukemia·2016
Same author

VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.

Oncogene·2016
Same author

Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.

Cell death & disease·2014
Same author

Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody.

Physics in medicine and biology·2011
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Monoclonal antibody therapy shows promise for treating blood cancers like leukemia. Advances in antibody engineering and drug conjugation are improving effectiveness for both large tumor burdens and minimal residual disease.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Monoclonal antibody (mAb) therapy is a rapidly advancing field in cancer treatment.
  • Hematopoietic neoplasms are particularly amenable to mAb therapy due to their biological characteristics and mAb pharmacology.
  • Significant progress has been made over the past decade in developing more effective mAb-based treatments.

Purpose of the Study:

  • To review the progress and current status of monoclonal antibody therapy in treating leukemias.
  • To highlight the advancements in antigen-antibody systems, antibody engineering, and drug conjugation.

Main Methods:

  • Review of recent clinical trials and research in monoclonal antibody therapy for leukemias.
  • Analysis of developments in humanized monoclonal antibodies, toxin and radionuclide conjugates.

Related Experiment Videos

  • Examination of interactions between monoclonal antibodies and cytokines, such as interleukin-2.

    • Main Results:

    • Recent trials demonstrate significant therapeutic activity of monoclonal antibodies in leukemias.
    • Monoclonal antibodies are effective in ablating large tumor cell masses before bone marrow transplantation.
    • These therapies show efficacy in eliminating minimal residual disease both in vivo and ex vivo.

    Conclusions:

    • Monoclonal antibody therapy represents a highly promising approach for treating hematopoietic neoplasms, especially leukemias.
    • Continued advancements in antibody technology and understanding of immune interactions are driving clinical success.